[논문]Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies

Ju, Man-Seok; Jung, Sang Taek

doi:10.3390/ijms21218240

[해외논문] Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies 원문보기

International journal of molecular sciences, v.21 no.21, 2020년, pp.8240 -

Ju, Man-Seok (Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Korea) , Jung, Sang Taek (seok0801@korea.ac.kr)

Abstract ▼ AI-Helper

G-protein-coupled receptors (GPCR) transmit extracellular signals into cells to regulate a variety of cellular functions and are closely related to the homeostasis of the human body and the progression of various types of diseases. Great attention has been paid to GPCRs as excellent drug targets, and there are many commercially available small-molecule chemical drugs against GPCRs. Despite this, the development of therapeutic anti-GPCR antibodies has been delayed and is challenging due to the difficulty in preparing active forms of GPCR antigens, resulting from their low cellular expression and complex structures. Here, we focus on anti-GPCR antibodies that have been approved or are subject to clinical trials and present various technologies to prepare active GPCR antigens that enable the isolation of therapeutic antibodies to proceed toward clinical validation.

Keyword

참고문헌 (78)

1. Wu J. Xie N. Zhao X. Nice E.C. Huang C. Dissection of aberrant GPCR signaling in tumorigenesis―A systems biology approach Cancer Genom Proteom. 2012 9 37 50
2. New D.C. Wong Y.H. Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression J. Mol. Signal. 2007 2 2 10.1186/1750-2187-2-2 17319972

상세보기
3. Zougman A. Hutchins G.G. Cairns D.A. Verghese E. Perry S.L. Jayne D.G. Selby P.J. Banks R.E. Retinoic acid-induced protein 3: Identification and characterisation of a novel prognostic colon cancer biomarker Eur. J. Cancer. 2013 49 531 539 10.1016/j.ejca.2012.07.031 23021913

상세보기
4. Sriram K. Moyung K. Corriden R. Carter H. Insel P.A. GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors PLoS Biol. 2019 17 e3000434 10.1371/journal.pbio.3000434 31765370

상세보기
5. Feigin M.E. Xue B. Hammell M.C. Muthuswamy S.K. G-protein？coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion Proc. Natl. Acad. Sci. USA 2014 111 4191 4196 10.1073/pnas.1320239111 24599592

상세보기
6. Santos R. Ursu O. Gaulton A. Bento A.P. Donadi R.S. Bologa C.G. Karlsson A. Al-Lazikani B. Hersey A. Oprea T.I. A comprehensive map of molecular drug targets Nat. Rev. Drug Discov. 2017 16 19 34 10.1038/nrd.2016.230 27910877

상세보기
7. Rask-Andersen M. Masuram S. Schioth H.B. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication Annu. Rev. Pharmacol. Toxicol. 2014 54 9 26 10.1146/annurev-pharmtox-011613-135943 24016212

상세보기
8. Hauser A.S. Attwood M.M. Rask-Andersen M. Schioth H.B. Gloriam D.E. Trends in GPCR drug discovery: New agents, targets and indications Nat. Rev. Drug Discov. 2017 16 829 842 10.1038/nrd.2017.178 29075003

상세보기
9. Hauser A.S. Chavali S. Masuho I. Jahn L.J. Martemyanov K.A. Gloriam D.E. Babu M.M. Pharmacogenomics of GPCR Drug Targets Cell 2018 172 41 54 10.1016/j.cell.2017.11.033 29249361

상세보기
10. Igawa T. Tsunoda H. Kuramochi T. Sampei Z. Ishii S. Hattori K. Engineering the variable region of therapeutic IgG antibodies MAbs Taylor & Francis Abingdon, UK 2011 3 243 252 10.4161/mabs.3.3.15234 21406966
11. Dolgin E. First GPCR-directed antibody passes approval milestone Nat. Rev. Drug Discov. 2018 17 457 459 10.1038/nrd.2018.103 29950713

상세보기
12. Kasamon Y.L. Chen H. de Claro R.A. Nie L. Ye J. Blumenthal G.M. Farrell A.T. Pazdur R. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sezary Syndrome Clin. Cancer Res. 2019 25 7275 7280 10.1158/1078-0432.CCR-19-2030 31366601

상세보기
13. Hoogenboom H.R. Selecting and screening recombinant antibody libraries Nat. Biotechnol. 2005 23 1105 1116 10.1038/nbt1126 16151404

상세보기
14. Amgen Inc Erenumab (Aimovig™): US Prescribing Information 2018 Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf (accessed on 13 October 2020)
15. Kyowa Kirin Inc Mogamulizumab (POTELIGEO ® ): US Prescribing Information 2018 Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761051s000lbl.pdf (accessed on 13 October 2020)
16. OncoMed Pharmaceuticals Inc A Study of Vantictumab (OMP-18R5) in Combination with Docetaxel in Patients with Previously Treated NSCLC 2013 Available online: https://clinicaltrials.gov/ct2/show/NCT01957007 (accessed on 13 October 2020)
17. OncoMed Pharmaceuticals Inc A Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Locally Recurrent or Metastatic Breast Cancer 2013 Available online: https://clinicaltrials.gov/ct2/show/NCT01973309 (accessed on 13 October 2020)
18. OncoMed Pharmaceuticals Inc A Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer 2013 Available online: https://clinicaltrials.gov/ct2/show/NCT02005315 (accessed on 13 October 2020)
19. CytoDyn Inc PRO 140 in Treatment-Experienced HIV-1 Subjects 2019 Available online: https://clinicaltrials.gov/ct2/show/NCT03902522 (accessed on 13 October 2020)
20. Millennium Pharmaceuticals Inc Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis 2010 Available online: https://clinicaltrials.gov/ct2/show/NCT01199640?cond=plozalizumab&draw=2&rank=3 (accessed on 13 October 2020)
21. Bristol-Myers Squibb An Investigational Immuno-therapy Study of Ulocuplumab in Combination with Low Dose Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia 2014 Available online: https://clinicaltrials.gov/ct2/show/NCT02305563?cond=Ulocuplumab&draw=2&rank=4 (accessed on 13 October 2020)
22. Innate Pharma IPH5401 (Anti-C5aR) in Combination with Durvalumab in Patients with Advanced Solid Tumors (STELLAR-001) 2018 Available online: https://clinicaltrials.gov/ct2/show/NCT03665129 (accessed on 13 October 2020)
23. Gmax Biopharm LLC First Patient Dose of Glutazumab (GMA102) in the Phase II Clinical Trial for Treatment of Type 2 Diabetes 2017 Available online: http://www.gmaxbiopharm.com/newng2_detail/id/15.html (accessed on 13 October 2020)
24. REMD Biotherapeutics Inc Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects with Type 1 Diabetes Mellitus 2017 Available online: https://clinicaltrials.gov/ct2/show/NCT03117998 (accessed on 13 October 2020)
25. Bird Rock Bio Inc Safety tolerability, and PK of RYI-018 after Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) 2017 Available online: https://clinicaltrials.gov/ct2/show/NCT03261739 (accessed on 13 October 2020)
26. Lefkowitz R.J. Shenoy S.K. Transduction of receptor signals by beta-arrestins Science 2005 308 512 517 10.1126/science.1109237 15845844

상세보기
27. Webb D.R. Handel T.M. Kretz-Rommel A. Stevens R.C. Opportunities for functional selectivity in GPCR antibodies Biochem. Pharmacol. 2013 85 147 152 10.1016/j.bcp.2012.08.021 22975405

상세보기
28. Soto A.G. Smith T.H. Chen B. Bhattacharya S. Cordova I.C. Kenakin T. Vaidehi N. Trejo J. N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias Proc. Natl. Acad. Sci. USA 2015 112 E3600 E3608 10.1073/pnas.1508838112 26100877

상세보기
29. Markham A. Erenumab: First Global Approval Drugs 2018 78 1157 1161 10.1007/s40265-018-0944-0 29968151

상세보기
30. Subramaniam J.M. Whiteside G. McKeage K. Croxtall J.C. Mogamulizumab: First global approval Drugs 2012 72 1293 1298 10.2165/11631090-000000000-00000 22686619

상세보기
31. Smith D.C. Rosen L.S. Chugh R. Goldman J.W. Xu L. Kapoun A. Brachmann R.K. Dupont J. Stagg R.J. Tolcher A.W. First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors J. Clin. Oncol. 2013 31 2540 10.1200/jco.2013.31.15_suppl.2540 23733781

상세보기
32. Brain S.D. Grant A.D. Vascular actions of calcitonin gene-related peptide and adrenomedullin Physiol. Rev. 2004 84 903 934 10.1152/physrev.00037.2003 15269340

상세보기
33. Hay D.L. Pioszak A.A. Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles Annu. Rev. Pharmacol. Toxicol. 2016 56 469 487 10.1146/annurev-pharmtox-010715-103120 26514202

상세보기
34. Kee Z. Kodji X. Brain S.D. The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects Front. Physiol. 2018 9 1249 10.3389/fphys.2018.01249 30283343

상세보기
35. Liang Y.L. Khoshouei M. Deganutti G. Glukhova A. Koole C. Peat T.S. Radjainia M. Plitzko J.M. Baumeister W. Miller L.J. Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor Nature 2018 561 492 497 10.1038/s41586-018-0535-y 30209400

상세보기
36. King C.T. Gegg C.V. Hu S.N.-Y. Sen Lu H. Chan B.M. Berry K.A. Brankow D.W. Boone T.J. Kezunovic N. Kelley M.R. Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor ACS Pharmacol. Transl. Sci. 2019 2 485 490 10.1021/acsptsci.9b00061 32259079

상세보기
37. Booe J.M. Walker C.S. Barwell J. Kuteyi G. Simms J. Jamaluddin M.A. Warner M.L. Bill R.M. Harris P.W. Brimble M.A. Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor Mol. Cell 2015 58 1040 1052 10.1016/j.molcel.2015.04.018 25982113

상세보기
38. Shi L. Lehto S.G. Zhu D.X. Sun H. Zhang J. Smith B.P. Immke D.C. Wild K.D. Xu C. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor J. Pharmacol. Exp. Ther. 2016 356 223 231 10.1124/jpet.115.227793 26559125
39. Garces F. Mohr C. Zhang L. Huang C.S. Chen Q. King C. Xu C. Wang Z.L. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab) Cell Rep. 2020 30 1714 1723 10.1016/j.celrep.2020.01.029 32049005

상세보기
40. Goadsby P.J. Reuter U. Hallstrom Y. Broessner G. Bonner J.H. Zhang F. Sapra S. Picard H. Mikol D.D. Lenz R.A. A Controlled Trial of Erenumab for Episodic Migraine N. Engl. J. Med. 2017 377 2123 2132 10.1056/NEJMoa1705848 29171821

상세보기
41. Ishida T. Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer Cancer Sci. 2006 97 1139 1146 10.1111/j.1349-7006.2006.00307.x 16952304

상세보기
42. Sugiyama D. Nishikawa H. Maeda Y. Nishioka M. Tanemura A. Katayama I. Ezoe S. Kanakura Y. Sato E. Fukumori Y. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans Proc. Natl. Acad. Sci. USA 2013 110 17945 17950 10.1073/pnas.1316796110 24127572

상세보기
43. Shitara K. Hanai N. Shoji E. Sakurada M. Furuya A. Nakamura K. Niwa R. Shibata K. Yamasaki M. Method for producing recombinant antibody and antibody fragment thereof U.S. Patent 8,632,996 21 1 2014
44. Niwa R. Shoji-Hosaka E. Sakurada M. Shinkawa T. Uchida K. Nakamura K. Matsushima K. Ueda R. Hanai N. Shitara K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma Cancer Res. 2004 64 2127 2133 10.1158/0008-5472.CAN-03-2068 15026353

상세보기
45. Niwa R. Sakurada M. Kobayashi Y. Uehara A. Matsushima K. Ueda R. Nakamura K. Shitara K. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density Clin. Cancer Res. 2005 11 2327 2336 10.1158/1078-0432.CCR-04-2263 15788684

상세보기
46. Yano H. Ishida T. Inagaki A. Ishii T. Ding J. Kusumoto S. Komatsu H. Iida S. Inagaki H. Ueda R. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome Clin. Cancer Res. 2007 13 6494 6500 10.1158/1078-0432.CCR-07-1324 17975162

상세보기
47. Yoshie O. Matsushima K. CCR4 and its ligands: From bench to bedside Int. Immunol. 2014 27 11 20 10.1093/intimm/dxu079 25087232

상세보기
48. Ishida T. Joh T. Uike N. Yamamoto K. Utsunomiya A. Yoshida S. Saburi Y. Miyamoto T. Takemoto S. Suzushima H. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study J. Clin. Oncol. 2012 30 837 842 10.1200/JCO.2011.37.3472 22312108

상세보기
49. Clevers H. Nusse R. Wnt/beta-catenin signaling and disease Cell 2012 149 1192 1205 10.1016/j.cell.2012.05.012 22682243

상세보기
50. Gurney A. Axelrod F. Bond C.J. Cain J. Chartier C. Donigan L. Fischer M. Chaudhari A. Ji M. Kapoun A.M. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors Proc. Natl. Acad. Sci. USA 2012 109 11717 11722 10.1073/pnas.1120068109 22753465

상세보기
51. Li C. Yang M. Wang X. Zhang H. Yao C. Sun S. Liu Q. Pan H. Liu S. Huan Y. Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites Biochem. Pharmacol. 2018 150 46 53 10.1016/j.bcp.2018.01.029 29355505

상세보기
52. Yan H. Gu W. Yang J. Bi V. Shen Y. Lee E. Winters K.A. Komorowski R. Zhang C. Patel J.J. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys J. Pharmacol. Exp. Ther. 2009 329 102 111 10.1124/jpet.108.147009 19129372

상세보기
53. Pettus J. Reeds D. Cavaiola T.S. Boeder S. Levin M. Tobin G. Cava E. Thai D. Shi J. Yan H. Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial Diabetes Obes. Metab. 2018 20 1302 1305 10.1111/dom.13202 29283470

상세보기
54. Gilbert J. Lekstrom-Himes J. Donaldson D. Lee Y. Hu M. Xu J. Wyant T. Davidson M. MLN1202 Study Group Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region Am. J. Cardiol. 2011 107 906 911 10.1016/j.amjcard.2010.11.005 21247529

상세보기
55. Olson W.C. Rabut G.E. Nagashima K.A. Tran D.N. Anselma D.J. Monard S.P. Segal J.P. Thompson D.A. Kajumo F. Guo Y. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5 J. Virol. 1999 73 4145 4155 10.1128/JVI.73.5.4145-4155.1999 10196311

상세보기
56. Kuhne M.R. Mulvey T. Belanger B. Chen S. Pan C. Chong C. Cao F. Niekro W. Kempe T. Henning K.A. BMS-936564/MDX-1338: A fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies Clin. Cancer Res. 2013 19 357 366 10.1158/1078-0432.CCR-12-2333 23213054

상세보기
57. Massard C. Cassier P. Bendell J.C. Marie D.B. Blery M. Morehouse C. Ascierto M. Zerbib R. Mitry E. Tolcher A.W. 1203P―Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours Ann. Oncol. 2019 30 v492 10.1093/annonc/mdz253.029

상세보기
58. Zhang C. Jing S. Zhang H. Wang X. Chenjiang Y.A.O. Antibody Specifically Binding to GLP-1 R and Fusion Protein thereof with GLP-1 Patent U.S. Patent 10,059,773 28 8 2018
59. Trkola A. Ketas T.J. Nagashima K.A. Zhao L. Cilliers T. Morris L. Moore J.P. Maddon P.J. Olson W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140 J. Virol. 2001 75 579 588 10.1128/JVI.75.2.579-588.2001 11134270

상세보기
60. Lee K. Jung Y. Lee J.Y. Lee W.K. Lim D. Yu Y.G. Purification and characterization of recombinant human endothelin receptor type A Protein Expr. Purif. 2012 84 14 18 10.1016/j.pep.2012.04.011 22561246

상세보기
61. Corin K. Baaske P. Ravel D.B. Song J. Brown E. Wang X. Geissler S. Wienken C.J. Jerabek-Willemsen M. Duhr S. A robust and rapid method of producing soluble, stable, and functional G-protein coupled receptors PLoS ONE 2011 6 e23036 22039398

상세보기
62. Sarkar C.A. Dodevski I. Kenig M. Dudli S. Mohr A. Hermans E. Pluckthun A. Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity Proc. Natl. Acad. Sci. USA 2008 105 14808 14813 10.1073/pnas.0803103105 18812512

상세보기
63. Link A.J. Skretas G. Strauch E.M. Chari N.S. Georgiou G. Efficient production of membrane-integrated and detergent-soluble G protein-coupled receptors in Escherichia coli Protein Sci. 2008 17 1857 1863 10.1110/ps.035980.108 18593817

상세보기
64. Vukoti K. Kimura T. Macke L. Gawrisch K. Yeliseev A. Stabilization of functional recombinant cannabinoid receptor CB(2) in detergent micelles and lipid bilayers PLoS ONE 2012 7 e46290 23056277

상세보기
65. Liu S. Wang S. Lu S. DNA immunization as a technology platform for monoclonal antibody induction Emerg. Microbes Infect. 2016 5 1 12 10.1038/emi.2016.27

상세보기
66. Van der Woning B. De Boeck G. Blanchetot C. Bobkov V. Klarenbeek A. Saunders M. Waelbroeck M. Laeremans T. Steyaert J. Hultberg A. DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops MAbs Taylor & Francis Abingdon, UK 2016 8 1126 1135 10.1080/19420862.2016.1189050 27211075
67. Heimann A.S. Gupta A. Gomes I. Rayees R. Schlessinger A. Ferro E.S. Unterwald E.M. Devi L.A. Generation of G protein-coupled receptor antibodies differentially sensitive to conformational states PLoS ONE 2017 12 e0187306 10.1371/journal.pone.0187306 29091950

상세보기
68. Boshuizen R.S. Marsden C. Turkstra J. Rossant C.J. Slootstra J. Copley C. Schwamborn K. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2) MAbs Taylor & Francis Abingdon, UK 2014 6 1415 1424 10.4161/mabs.36237 25484047
69. Kushnir N. Streatfield S.J. Yusibov V. Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development Vaccine 2012 31 58 83 10.1016/j.vaccine.2012.10.083 23142589

상세보기
70. O’Rourke J.P. Peabody D.S. Chackerian B. Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform Curr. Opin. Virol. 2015 11 76 82 10.1016/j.coviro.2015.03.005 25829254

상세보기
71. Ho T.T. Nguyen J.T. Liu J. Stanczak P. Thompson A.A. Yan Y.G. Chen J. Allerston C.K. Dillard C.L. Xu H. Method for rapid optimization of recombinant GPCR protein expression and stability using virus-like particles Protein Expr. Purif. 2017 133 41 49 10.1016/j.pep.2017.03.002 28263854

상세보기
72. Rouck J.E. Krapf J.E. Roy J. Huff H.C. Das A. Recent advances in nanodisc technology for membrane protein studies (2012？2017) FEBS Lett. 2017 591 2057 2088 10.1002/1873-3468.12706 28581067

상세보기
73. Denisov I.G. Sligar S.G. Nanodiscs in Membrane Biochemistry and Biophysics Chem. Rev. 2017 117 4669 4713 10.1021/acs.chemrev.6b00690 28177242

상세보기
74. Kretz-Rommel A. Shi L. Ferrini R. Yang T. Xu F. Campion B. Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor U.S. Patent 16/257,511 17 10 2019
75. Mallat A. Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver Am. J. Physiol. Gastrointest. Liver Physiol. 2008 294 G9 G12 10.1152/ajpgi.00467.2007 17975129

상세보기
76. Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce? Nat. Rev. Drug Discov. 2008 7 438 455 10.1038/nrd2553 18446159

상세보기
77. Osei-Hyiaman D. DePetrillo M. Pacher P. Liu J. Radaeva S. Batkai S. Harvey-White J. Mackie K. Offertaler L. Wang L. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity J. Clin. Investig. 2005 115 1298 1305 10.1172/JCI200523057 15864349

상세보기
78. Dodd R.B. Wilkinson T. Schofield D.J. Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies Biodrugs 2018 32 339 355 10.1007/s40259-018-0289-y 29934752

상세보기

LOADING...

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증